Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?-Reference-Cited by-同舟云学术

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Published:2015-12-17 Issue:25 Volume:126 Page:2713-2719
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chretien Marie-Lorraine¹,Corre Jill²,Lauwers-Cances Valerie³,Magrangeas Florence⁴,Cleynen Alice²,Yon Edwige³,Hulin Cyrille⁵,Leleu Xavier⁶,Orsini-Piocelle Frederique⁷,Blade Jean-Sebastien⁵,Sohn Claudine⁸,Karlin Lionel⁹,Delbrel Xavier¹⁰,Hebraud Benjamin¹¹,Roussel Murielle¹¹,Marit Gerald¹²,Garderet Laurent¹³,Mohty Mohamad¹³,Rodon Philippe¹⁴,Voillat Laurent¹⁵,Royer Bruno¹⁶,Jaccard Arnaud¹⁷,Belhadj Karim¹⁸,Fontan Jean¹⁹,Caillot Denis¹,Stoppa Anne-Marie²⁰,Attal Michel¹¹,Facon Thierry⁶,Moreau Philippe²¹,Minvielle Stephane⁴,Avet-Loiseau Hervé²

Affiliation:

1. Department of Hematology, Centre Hospitalier Universitaire, Dijon, France;

2. Unit for Genomics in Myeloma, Institut Universitaire du Cancer-Oncopole, and Centre de Recherches sur le Cancer de Toulouse INSERM 1037, Toulouse, France;

3. Service d’Epidemiologie, Centre Hospitalier Universitaire, Toulouse, France;

4. Unité Mixte de Génomique du Cancer, Centre Hospitalier Universitaire, and INSERM U892, Nantes, France;

5. Department of Hematology, Centre Hospitalier Universitaire, Nancy, France;

6. Department of Hematology, Centre Hospitalier Universitaire, Lille, France;

7. Department of Hematology, Centre Hospitalier, Annecy, France;

8. Department of Hematology, Hopital Inter-Armées, Toulon, France;

9. Department of Hematology, Centre Hospitalier, Toulon, France;

10. Department of Hematology, Centre Hospitalier, Pau, France;

11. Department of Hematology, Institut Universitaire du Cancer, Toulouse, France;

12. Department of Hematology, Centre Hospitalier Universitaire, Bordeaux, France;

13. Department of Hematology, Centre Hospitalier Universitaire St-Antoine, Paris, France;

14. Department of Hematology, Centre Hospitalier, Perigueux, France;

15. Department of Hematology, Centre Hospitalier, Chalon sur Saone, France;

16. Department of Hematology, Centre Hospitalier Universitaire, Amiens, France;

17. Department of Hematology, Centre Hospitalier Universitaire, Limoges, France;

18. Department of Hematology, Centre Hospitalier Universitaire, Créteil, France;

19. Department of Hematology, Centre Hospitalier Universitaire, Besançon, France;

20. Department of Hematology, Institut Paoli Calmettes, Marseille, France; and

21. Department of Hematology, Centre Hospitalier Universitaire, Nantes, France

Abstract

Key Points In myeloma patients, trisomy 3 improved time to progression and trisomies 3 and/or 5 improved overall survival. In contrast, trisomy 21 significantly worsened overall survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/25/2713/1390316/2713.pdf

Reference20 articles.

1. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.;Gertz;Blood,2005

2. Clinical and biologic implications of recurrent genomic aberrations in myeloma.;Fonseca;Blood,2003

3. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.;Avet-Loiseau;Blood,2007

4. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.;Hanamura;Blood,2006

5. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.;Avet-Loiseau;J Clin Oncol,2012

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

2. A rare presentation and treatment challenges for multiple myeloma in down syndrome: A case report and literature review;Clinical Case Reports;2024-07

3. Impact of Clonal Heterogeneity in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma;Haematologica;2024-01-11

5. Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10